SanBio is focused on therapies for neurological disorders such as stroke, spinal cord injury, Parkinson's disease and multiple sclerosis.

SanBio is a scientific leader in cell therapies for regenerative medicine. SanBio's products have achieved extraordinary results in animal models of a number of important disorders and having received FDA Investigational New Drug approval, have initiated a Phase I/IIa clinical trial for stroke disability.

SanBio is now recruiting patients for a clinical trial testing a new cell therapy for stable stroke.

Use this UCSF questionnaire
to determine your eligiblity. ABOUT THE STUDY

A clinical trial is testing SB623, an adult stem cell therapy. In animal studies, measurable improvements in use of limbs have been shown. In this clinical study, safety as well as therapeutic potential will be evaluated.
Read more....

Pittsburgh (CBS2 KDKA): Researchers Testing Stem Cells as Treatment for Stroke Recovery

News

March 4, 2013 Stanford-based research seeks to help stroke patients.
February 4, 2013 Northwestern Medicine Researchers Investigate Stem Cell Therapy for Stroke.
January 14, 2013 SanBio Announces Enrollment of the Second Cohort of Patients in its Clinical Trial of Stem Cell Therapy for Chronic Stroke.
June 04, 2012 Researchers Testing Stem Cells as Treatment for Stroke Recovery.